Valeda Photobiomodulation for Selected Patients with Dry AMD
In short
The Valeda light-delivery system uses photobiomodulation for selected patients with dry age-related macular degeneration. It is not a treatment for every form or stage of macular disease, and a retinal assessment is needed to discuss eligibility, realistic expectations and continuing care.
View referencesValeda is a prescription light-based device used for selected patients with dry age-related macular degeneration (AMD). It delivers photobiomodulation and is intended to improve visual acuity in a defined patient population.
Who may be considered?
A retinal specialist must confirm the AMD type and stage and check the device indications and precautions. It is not a general treatment for all macular disease or a substitute for wet-AMD care.
Benefits and limitations
Clinical results describe average outcomes in selected patients. They do not establish guaranteed benefit, regeneration of damaged cells or an assured halt to progression. Treatment requires monitoring, including review for changes in AMD. The clinician should discuss the individual benefit–risk balance.
About this health information
This content provides general health information and does not replace an individual diagnosis or treatment recommendation. An eye examination is needed for an assessment of your circumstances.
Content enquiries and correction requests: [email protected]
